For more information regarding the endpoints, refer to the 'ToxCast Endpoints' file on the
DOWNLOAD page.
ToxCast Endpoints for intended target type: RNA
Assay Name | Tissue | Target Gene ID | Target HGNC Symbol | Target UniProt ID | Response | AC50 value |
---|
LTEA_HepaRG_CYP1A1 | Liver | 1543 | CYP1A1 | P04798 | Activatory | 28.01 μM |
LTEA_HepaRG_CYP1A2 | Liver | 1544 | CYP1A2 | P05177 | Activatory | 33.45 μM |
LTEA_HepaRG_UGT1A1 | Liver | 54658 | UGT1A1 | P22309 | Activatory | 36.52 μM |
ToxCast Endpoints for intended target type: Protein
Assay Name | Tissue | Target Gene ID | Target HGNC Symbol | Target UniProt ID | Response | AC50 value |
---|
TOX21_ERa_BLA_Antagonist_ratio | Kidney | 2099 | ESR1 | P03372 | Loss | 58.61 μM |
TOX21_AhR_LUC_Agonist | Liver | 196 | AHR | P35869 | Gain | 57.31 μM |
TOX21_ERR_LUC_Antagonist | Kidney | 2101 | ESRRA | P11474 | Loss | 13.64 μM |
TOX21_ERb_BLA_Antagonist_ratio | Kidney | 2100 | ESR2 | Q92731 | Loss | 3.42 μM |
TOX21_p450_CYP2D6_Antagonist | | 1565 | CYP2D6 | P10635 | Loss | 59.19 μM |
TOX21_p450_CYP2C19_Antagonist | | 1557 | CYP2C19 | P33261 | Loss | 45.47 μM |
TOX21_p450_CYP2C9_Antagonist | | 1559 | CYP2C9 | P11712 | Loss | 66.94 μM |
TOX21_p450_CYP1A2_Antagonist | | 1544 | CYP1A2 | P05177 | Loss | 47.42 μM |
No ToxCast endpoints for intended target type: Molecular Messengers
ToxCast Endpoints for intended target type: Pathway
Assay Name | Tissue | Target Gene ID | Target HGNC Symbol | Target UniProt ID | Response | AC50 value |
---|
OT_FXR_FXRSRC1_1440 | Kidney | 6714|9971 | NR1H4|SRC | P12931|Q96RI1 | Gain | 1.96 μM |
OT_NURR1_NURR1RXRa_1440 | Kidney | 4929|6256 | NR4A2|RXRA | P19793|P43354 | Gain | 2.33 μM |
ACEA_AR_antagonist_80hr | Prostate | 367 | AR | P10275 | Loss | 18.15 μM |
ToxCast Endpoints for intended target type: Cellular
Assay Name | Tissue | Response | AC50 value |
---|
BSK_3C_Proliferation | Vascular | Inhibitory | 13.20 μM |
BSK_hDFCGF_Proliferation | Skin | Inhibitory | 7.71 μM |
ACEA_AR_agonist_AUC_viability | Prostate | Loss | 5.62 μM |
ACEA_AR_antagonist_AUC_viability | Prostate | Loss | 8.97 μM |
No ToxCast endpoints for intended target type: Extracellular